Trial Profile
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab Maintenance in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms MAGNIFY
- Sponsors Celgene Corporation
- 09 Apr 2024 Planned primary completion date changed from 15 Jan 2024 to 12 Apr 2024.
- 09 Jan 2024 Planned primary completion date changed from 16 Oct 2023 to 15 Jan 2024.
- 27 Sep 2023 Planned primary completion date changed from 18 Sep 2023 to 16 Oct 2023.